Tristel (GB:TSTL) has released an update.
Tristel plc has reported a robust financial performance for the fiscal year ending June 30, 2024, with revenues soaring by 16.4% to £41.9 million and pre-tax profits climbing to at least £8.0 million, surpassing both market and internal expectations. The company, specializing in infection prevention products, remains debt-free and has strengthened its cash position, while expanding into North American markets with FDA and Health Canada approvals. As the CEO transitions, Tristel is poised to leverage its niche in medical device decontamination and expand into hospital surface disinfection.
For further insights into GB:TSTL stock, check out TipRanks’ Stock Analysis page.
